Literature DB >> 21784168

The challenge of developing robust drugs to overcome resistance.

Amy C Anderson1, Michael P Pollastri, Celia A Schiffer, Norton P Peet.   

Abstract

Drug resistance is problematic in microbial disease, viral disease and cancer. Understanding at the outset that resistance will impact the effectiveness of any new drug that is developed for these disease categories is imperative. In this Feature, we detail approaches that have been taken with selected drug targets to reduce the susceptibility of new drugs to resistance mechanisms. We will also define the concepts of robust drugs and resilient targets, and discuss how the design of robust drugs and the selection of resilient targets can lead to successful strategies for combating resistance.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784168      PMCID: PMC3604877          DOI: 10.1016/j.drudis.2011.07.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  82 in total

1.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors:  Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

2.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Targeted covalent drugs of the kinase family.

Authors:  Juswinder Singh; Russell C Petter; Arthur F Kluge
Journal:  Curr Opin Chem Biol       Date:  2010-07-06       Impact factor: 8.822

6.  FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.

Authors:  E Lierman; L Michaux; E Beullens; P Pierre; P Marynen; J Cools; P Vandenberghe
Journal:  Leukemia       Date:  2009-02-12       Impact factor: 11.528

7.  Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.

Authors:  Christian Oefner; Monica Bandera; Andreas Haldimann; Heike Laue; Henk Schulz; Seema Mukhija; Sandro Parisi; Laurent Weiss; Sergio Lociuro; Glenn E Dale
Journal:  J Antimicrob Chemother       Date:  2009-02-11       Impact factor: 5.790

8.  New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.

Authors:  Peter Angehrn; Stefan Buchmann; Christoph Funk; Erwin Goetschi; Hans Gmuender; Paul Hebeisen; Dirk Kostrewa; Helmut Link; Thomas Luebbers; Raffaello Masciadri; Joergen Nielsen; Peter Reindl; Fabienne Ricklin; Anne Schmitt-Hoffmann; Frank-Peter Theil
Journal:  J Med Chem       Date:  2004-03-11       Impact factor: 7.446

9.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

Review 10.  The ATP-binding site of type II topoisomerases as a target for antibacterial drugs.

Authors:  Anthony Maxwell; David M Lawson
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

View more
  9 in total

1.  Combatting Drug-Resistant Bacteria with Gyrase and Topoisomerase IV Inhibitors: Patent Highlight.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2012-08-27       Impact factor: 4.345

Review 2.  Winning the arms race by improving drug discovery against mutating targets.

Authors:  Amy C Anderson
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

3.  miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.

Authors:  Ye Zhang; Xiujuan Qu; Ce Li; Yibo Fan; Xiaofang Che; Ximing Wang; Ying Cai; Xuejun Hu; Yunpeng Liu
Journal:  Tumour Biol       Date:  2014-11-19

4.  Effect of pH on anti-rotavirus activity by comestible juices and proanthocyanidins in a cell-free assay system.

Authors:  Steven M Lipson; Fatma S Ozen; Laina Karthikeyan; Ronald E Gordon
Journal:  Food Environ Virol       Date:  2012-09-12       Impact factor: 4.034

5.  Fused-Ring Oxazolopyrrolopyridopyrimidine Systems with Gram-Negative Activity.

Authors:  Yiyuan Chen; Jonathan G Moloney; Kirsten E Christensen; Mark G Moloney
Journal:  Antibiotics (Basel)       Date:  2017-01-13

6.  Embryonic zebrafish xenograft assay of human cancer metastasis.

Authors:  David Hill; Lanpeng Chen; Ewe Snaar-Jagalska; Bill Chaudhry
Journal:  F1000Res       Date:  2018-10-22

7.  miRNA-765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells.

Authors:  Wan Lin; Yu Miao; Xiangkun Meng; Ying Huang; Wanli Zhao; Jigang Ruan
Journal:  FEBS Open Bio       Date:  2020-04-18       Impact factor: 2.693

8.  RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner.

Authors:  Zhen Tan; Si Shi; Jin Xu; Xiaomeng Liu; Yubin Lei; Bo Zhang; Jie Hua; Qingcai Meng; Wei Wang; Xianjun Yu; Chen Liang
Journal:  Oncogene       Date:  2022-04-14       Impact factor: 8.756

Review 9.  Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.

Authors:  Kwaku Appiah-Kubi; Ying Wang; Hai Qian; Min Wu; Xiaoyuan Yao; Yan Wu; Yongchang Chen
Journal:  Tumour Biol       Date:  2016-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.